We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Customizable AI Tool Helps Pathologists Identify Diseased Cells

By LabMedica International staff writers
Posted on 26 Jun 2024
Print article
Image: Green boxes highlight plasma cells — an indicator of infection — in a sample of the tissue lining the uterus (Photo courtesy of Zou lab and Montine lab)
Image: Green boxes highlight plasma cells — an indicator of infection — in a sample of the tissue lining the uterus (Photo courtesy of Zou lab and Montine lab)

Pathologists are tasked with examining body fluids or tissues to diagnose diseases, a process that involves distinguishing rare disease-indicating cells from thousands of normal cells under a microscope. This skill requires extensive training. Artificial intelligence (AI) can assist by learning to differentiate between healthy and diseased cells from digital pathology images. However, traditional AI tools, once trained, lack flexibility. They are designed for specific tasks, such as identifying cancer cells in one organ but not another, and might not align perfectly with a pathologist's specific needs in different scenarios. Now, a collaborative team of computer scientists and physicians has developed a new AI tool that not only identifies diseased cells but also adapts to a pathologist’s requirements.

Developed at Stanford Medicine (Stanford, CA, USA), the tool, named nuclei.io, functions like a human assistant that evolves with feedback. Starting with the basic function of recognizing different cell types by their nuclei, which house genetic material, the tool is designed to improve through interaction. Within an hour of use, nuclei.io can learn to identify the specific cells of interest to a pathologist, enhancing both the speed and accuracy of their work. During its initial trials at Stanford Medicine, the tool demonstrated its ability to speed up and enhance the diagnostic processes, reducing the time and increasing diagnostic accuracy.

In practical tests, where Stanford pathologists used the tool for tasks such as identifying immune cells in uterine biopsies for endometritis or detecting colon cancer cells in lymph nodes, nuclei.io reduced diagnostic times significantly—from 209 seconds to 79 seconds. The AI assistance made the pathologists 62% faster and 72% more accurate in their diagnoses. It is important to note that nuclei.io does not aim to replace the pathologist but rather guide them more efficiently to areas requiring detailed examination. This is part of a broader aim to ensure patients receive rapid and accurate diagnoses. Stanford Medicine pathologists are continuing to evaluate the tool’s effectiveness on a range of diseased cells, showcasing its potential to become a versatile aid in pathology.

“As we face a growing shortage of pathologists, AI tools that work in tandem with doctors have the potential to speed up some of the more tedious, time-consuming parts of our job,” said professor and chair of pathology Thomas Montine, MD, PhD. “One of the strengths of nuclei.io is that it is agnostic to application. This can be a powerful tool for interpreting any biopsy where we are trying to differentiate healthy and malignant cells. That’s not true of any other major AI tool being used in pathology right now.”

Related Links:
Stanford Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Blood Gas and Chemistry Analysis System
Edan i500

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.